{"id":692449,"date":"2022-10-05T09:19:55","date_gmt":"2022-10-05T13:19:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-host-rd-event-november-10-2022\/"},"modified":"2022-10-05T09:19:55","modified_gmt":"2022-10-05T13:19:55","slug":"mink-therapeutics-to-host-rd-event-november-10-2022","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-host-rd-event-november-10-2022\/","title":{"rendered":"MiNK Therapeutics to Host R&amp;D Event November 10, 2022"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:left\">\n          <em>Experts in disease pathways discuss clinical data of allo-iNKTs<\/em>\n        <\/li>\n<li style=\"text-align:left\">\n          <em>R&amp;D strategy driving pipeline momentum, productivity, and innovation<\/em>\n        <\/li>\n<li>\n          <em>Internal scalable manufacturing of fully allogeneic iNKT cells; expanded capacity to ~700,000 doses<\/em>\n        <\/li>\n<li>\n          <em>R&amp;D event: November 10<\/em><br \/>\n          <sup><br \/>\n            <em>th<\/em><br \/>\n          <\/sup><br \/>\n          <em> from 4:00-6:00 pm ET, Boston, MA, and webcast<\/em>\n        <\/li>\n<\/ul>\n<p>NEW YORK, Oct.  05, 2022  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Cxk-H5e8d1QypxlaaBI0fscRKunHQYdUzBbXUfkpSJcZuiHFxXJK5-wSydNj9RmOnxVADIFYy1paTi23o0DSAUl_7lTvQJVzb0r8YLJFr68=\" rel=\"nofollow noopener\" target=\"_blank\">MiNK Therapeutics<\/a>, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced the company will host an in-person and virtual Research &amp; Development Day on Thursday, November 10<sup>th<\/sup>, 2022 from 4:00-6:00 PM ET in Boston, MA, and via webcast.<\/p>\n<p>The R&amp;D event will focus on the Company\u2019s novel iNKT cell therapy platform and highlight its five presentations at the Society for Immunotherapy of Cancer\u2019s (SITC) annual meeting. During the event, speakers will showcase recent developments in MiNK\u2019s clinical and next-generation programs, including the first data from the ongoing phase 1 trial of iNKTs alone and in combination with approved anti-PD-1 inhibitors in solid tumor cancers, data from the novel FAP-CAR-iNKT program, and internal high throughput cGMP manufacturing capabilities.<\/p>\n<p>The program will feature leaders in immuno-oncology and cell therapy, including members of the Company\u2019s management team and external thought leaders including:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>Terese Hammond<\/strong>, M.D., <em>Associate Program Medical Director, Providence Saint John\u2019s Health Center; Director, SCoRE (Sound Center of Research Excellence).<\/em><\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>Lydia Lynch<\/strong>, Ph.D., <em>Associate Professor of Medicine<\/em><em>, <\/em><em>Brigham and Women&#8217;s Hospital, Harvard Medical School.<\/em><\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>Manuel Hidalgo<\/strong>, M.D, Ph.D., <em>Chief of the Division of Hematology and Medical Oncology at Weill Cornell Department of Medicine.<\/em><\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>David Einstein<\/strong>, M.D., <em>Genitourinary Oncologist, Beth Israel Deaconess Medical Center; Assistant Professor, Harvard Medical School.<\/em><\/li>\n<\/ul>\n<p>The event will be webcasted live and institutional investors and analysts are invited to attend in person. Individuals interested in attending the event in person should contact MiNK Therapeutics Investor Relations at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TBmRL8rtMHWqiciprwrKu4FKFvVUlkM3EBM-Y84yauQu98YwpyUZFuNQybrJGzIwVsh1p-mZK5KIvJiF3osNOftnmisBz5lHhA4Lx1K4LVNWyBjgfmAHz5E4YYCdb0Uk\" rel=\"nofollow noopener\" target=\"_blank\">investor@minktherapeutics.com<\/a>. The live webcast will be available on the Events &amp; Presentations page of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8OPDccWKLpUDRiKbqyOaUA8GO2wx3Q-6A9F7EkFtIDhov6PFQlZaBhWAcaD7lo4z5bX10vAODKOtjR3seKqkx_m4f5zxjHJo6ZRhToNKvB9101yYmbyoJjC6cicAX-b1BXcGIy0RQF9CqJqJsJMPEAkYbLMxKE6iTwn5QuzZTKi4lRLdf5HKwXELIiS9H__PM8HkrTpemQ-qkbX43FwXzg==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/investor.minktherapeutics.com\/events-and-presentations<\/a>. To register for the webcast, please click <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kuhVOEjq9OWYwTTzTzN-sZ69F8C90vh4Wxm6lpjni9a3Q6QLTic0HE0MbB1U1ezu98jU2_KtC1ZdQZiCQuouBu6JWM0YR3Rf9zXYpGGFpUv5ayu7uCmlilTzOEnF_MitX4lHrhT5Rtx1TXxTSEU1KdUzsRn9nEdEPntbVA7X-a0=\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>. Following the webcast an archived version will be available on the MiNK website.<\/p>\n<p>\n        <strong><br \/>\n          <u>About MiNK Therapeutics<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https:\/\/minktherapeutics.com\/.<\/p>\n<p>\n        <strong><br \/>\n          <u>Contact<br \/><\/u><br \/>\n        <\/strong>Kimberly Ha<br \/>KKH Advisors<br \/>917-291-5744<br \/>kimberly.ha@kkhadvisors.com<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQ3MSM1MTg4ODQ5IzIyMjMyMTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MWE2M2ZjNDgtMjQ3NS00NDZhLTk4NTUtYjU1ZjllMWM5MTg2LTEyMzQ3NjQ=\/tiny\/MiNK-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Experts in disease pathways discuss clinical data of allo-iNKTs R&amp;D strategy driving pipeline momentum, productivity, and innovation Internal scalable manufacturing of fully allogeneic iNKT cells; expanded capacity to ~700,000 doses R&amp;D event: November 10 th from 4:00-6:00 pm ET, Boston, MA, and webcast NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced the company will host an in-person and virtual Research &amp; Development Day on Thursday, November 10th, 2022 from 4:00-6:00 PM ET in Boston, MA, and via webcast. The R&amp;D event will focus on the Company\u2019s novel iNKT cell &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-host-rd-event-november-10-2022\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MiNK Therapeutics to Host R&amp;D Event November 10, 2022&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-692449","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MiNK Therapeutics to Host R&amp;D Event November 10, 2022 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-host-rd-event-november-10-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MiNK Therapeutics to Host R&amp;D Event November 10, 2022 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Experts in disease pathways discuss clinical data of allo-iNKTs R&amp;D strategy driving pipeline momentum, productivity, and innovation Internal scalable manufacturing of fully allogeneic iNKT cells; expanded capacity to ~700,000 doses R&amp;D event: November 10 th from 4:00-6:00 pm ET, Boston, MA, and webcast NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced the company will host an in-person and virtual Research &amp; Development Day on Thursday, November 10th, 2022 from 4:00-6:00 PM ET in Boston, MA, and via webcast. The R&amp;D event will focus on the Company\u2019s novel iNKT cell &hellip; Continue reading &quot;MiNK Therapeutics to Host R&amp;D Event November 10, 2022&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-host-rd-event-november-10-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-05T13:19:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQ3MSM1MTg4ODQ5IzIyMjMyMTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-host-rd-event-november-10-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-host-rd-event-november-10-2022\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MiNK Therapeutics to Host R&amp;D Event November 10, 2022\",\"datePublished\":\"2022-10-05T13:19:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-host-rd-event-november-10-2022\\\/\"},\"wordCount\":459,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-host-rd-event-november-10-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTQ3MSM1MTg4ODQ5IzIyMjMyMTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-host-rd-event-november-10-2022\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-host-rd-event-november-10-2022\\\/\",\"name\":\"MiNK Therapeutics to Host R&amp;D Event November 10, 2022 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-host-rd-event-november-10-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-host-rd-event-november-10-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTQ3MSM1MTg4ODQ5IzIyMjMyMTE=\",\"datePublished\":\"2022-10-05T13:19:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-host-rd-event-november-10-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-host-rd-event-november-10-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-host-rd-event-november-10-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTQ3MSM1MTg4ODQ5IzIyMjMyMTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTQ3MSM1MTg4ODQ5IzIyMjMyMTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-host-rd-event-november-10-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MiNK Therapeutics to Host R&amp;D Event November 10, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MiNK Therapeutics to Host R&amp;D Event November 10, 2022 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-host-rd-event-november-10-2022\/","og_locale":"en_US","og_type":"article","og_title":"MiNK Therapeutics to Host R&amp;D Event November 10, 2022 - Market Newsdesk","og_description":"Experts in disease pathways discuss clinical data of allo-iNKTs R&amp;D strategy driving pipeline momentum, productivity, and innovation Internal scalable manufacturing of fully allogeneic iNKT cells; expanded capacity to ~700,000 doses R&amp;D event: November 10 th from 4:00-6:00 pm ET, Boston, MA, and webcast NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced the company will host an in-person and virtual Research &amp; Development Day on Thursday, November 10th, 2022 from 4:00-6:00 PM ET in Boston, MA, and via webcast. The R&amp;D event will focus on the Company\u2019s novel iNKT cell &hellip; Continue reading \"MiNK Therapeutics to Host R&amp;D Event November 10, 2022\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-host-rd-event-november-10-2022\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-05T13:19:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQ3MSM1MTg4ODQ5IzIyMjMyMTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-host-rd-event-november-10-2022\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-host-rd-event-november-10-2022\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MiNK Therapeutics to Host R&amp;D Event November 10, 2022","datePublished":"2022-10-05T13:19:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-host-rd-event-november-10-2022\/"},"wordCount":459,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-host-rd-event-november-10-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQ3MSM1MTg4ODQ5IzIyMjMyMTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-host-rd-event-november-10-2022\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-host-rd-event-november-10-2022\/","name":"MiNK Therapeutics to Host R&amp;D Event November 10, 2022 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-host-rd-event-november-10-2022\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-host-rd-event-november-10-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQ3MSM1MTg4ODQ5IzIyMjMyMTE=","datePublished":"2022-10-05T13:19:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-host-rd-event-november-10-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-host-rd-event-november-10-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-host-rd-event-november-10-2022\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQ3MSM1MTg4ODQ5IzIyMjMyMTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQ3MSM1MTg4ODQ5IzIyMjMyMTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-host-rd-event-november-10-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MiNK Therapeutics to Host R&amp;D Event November 10, 2022"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=692449"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692449\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=692449"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=692449"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=692449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}